ASTELLAS ENDS DEVELOPMENT OF ALZHEIMER'S DRUG

Astellas Pharma announced that it has decided to discontinue development of the Alzheimer's disease compound FK962.

Astellas had started Phase II trials for FK962 for Alzheimer's disease in the U.S. and Canada. After careful review of the Phase II interim analysis clinical data, Astellas has decided to discontinue further development since the data reviewed did not indicate clear efficacy of the compound for the treatment of mild to moderate Alzheimer's disease.